nonalcoholic%20fatty%20liver%20disease
NONALCOHOLIC FATTY LIVER DISEASE

Nonalcoholic fatty liver disease is having excessive fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes.

It is considered as a hepatic manifestation of metabolic syndrome.

Progression of nonalcoholic fatty liver disease is variable.

Introduction

  • Fatty liver is usually an incidental finding on abdominal imaging that reveals hepatic steatosis and laboratory study results of elevated liver enzymes
  • Considered as hepatic manifestation of metabolic syndrome (obesity, type 2 diabetes mellitus, insulin resistance, dyslipidemia and hypertension)
  • Most common liver disorder in the Western countries and becoming a serious health issue in many Asian countries
  • Progression of nonalcoholic fatty liver disease (NAFLD) is variable; ranges from hepatic steatosis through inflammatory nonalcoholic steatohepatitis (NASH) to fibrosis or cirrhosis
  • Major cause of mortality in patients with NAFLD is cardiovascular disease

Definition

  • Excessive hepatic fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes

Signs and Symptoms

  • Patient usually presents asymptomatic but may describe vague right upper quadrant pain, fatigue and malaise

Risk Factors

  • Obesity
  • Insulin resistance/metabolic syndrome
  • High-calorie diet with saturated fats, refined carbohydrates, sugar-sweetened beverages and high fructose
  • Jejunoileal bypass surgery
  • Highest risk in 40-65 years old
  • Higher risk in Hispanics and Asians while lower risk in African-Americans
  • Genetic predisposition
  • Drugs and toxins (eg Amiodarone, Coralgil, corticosteroids, synthetic estrogens, Methotrexate, IV Tetracycline)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

12 Apr 2017
Patients with fibromyalgia syndrome (FMS) are at an increased risk of peptic ulcer disease (PUD), a new study shows.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.
01 Jun 2015
A mixture of the flavonoids diosmin, troxerutin, and hesperidin is safe and effective for the symptomatic management of patients with acute haemorrhoidal disease, a prospective, randomised, triple-blind, controlled trial revealed.